Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VX-770 crossover study in cystic fibrosis with G551D mutation and preserved lung function
2010-020546-96Phase 2Completed
- Sponsor
- Vertex Pharmaceuticals
- Start
- Aug 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of ivacaftor in cystic fibrosis (CF) (2 arms), sponsored by Vertex Pharmaceuticals. Primary endpoint: Absolute change from baseline in lung clearance index. Started Aug 2010; status: completed.
02
Drugs
ivacaftor
03
Conditions
cystic fibrosis (CF)
Beyond the preview
Go deeper on 2010-020546-96.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-020546-96.